Joginder Sharma bowled the key final over when India beat arch-rivals Pakistan in the first Twenty20 World Cup cricket final in 2007, but says he faces more pressure as a police officer making sure people stay home during the coronavirus crisis.
The International Cricket Council (ICC) and others have hailed the efforts of the 36-year-old as he hits the streets of India in his role as an officer of the law.
"Obviously this contribution is much bigger because people are losing their lives," Sharma told AFP from Hisar in Haryana where he is now a superintendent.
"It was also a big thing, winning the World Cup for India, but here we have to save the nation. And even if I am playing a small part in this, then it is huge."
Sharma has been leading a team trying to keep people off the streets during a 21-day lockdown ordered by the government to halt the spread of the virus. India has now reported 29 deaths from more than 1,000 cases, but experts believe there are many more.
Thousands of people have been arrested across the country for flouting the curfew.
The ICC said Sharma had gone from World Cup hero to "real world hero" as it released a picture of the all-rounder in India cricket colours and his khaki police uniform.
Sharma, who played just four one-day internationals and four T20 matches, said he is using cricket's spirit of teamwork to tackle the crisis.
"It was the nature of my sport, which is a team game and players work together to make things happen. So now we have to help each other and the biggest help will be to stay inside our homes," said Sharma.
"This is the only way to fight coronavirus. Feed the hungry, help the poor. Say no to social gatherings, go out just for getting essentials, but maintain social distance."
Sharma added that his "extreme fitness levels" and fame also come in handy as an officer on the beat.
"People know me and recognise me and that helps putting my point across. But now I am a police officer and this is my duty."
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.